TriSalus Life Sciences, Inc.
TLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,566 | $11,213 | $9,167 | $8,261 |
| % Growth | 3.1% | 22.3% | 11% | – |
| Cost of Goods Sold | $1,906 | $1,802 | $1,495 | $1,216 |
| Gross Profit | $9,660 | $9,411 | $7,672 | $7,045 |
| % Margin | 83.5% | 83.9% | 83.7% | 85.3% |
| R&D Expenses | $5,176 | $3,923 | $3,296 | $2,959 |
| G&A Expenses | $6,659 | $5,657 | $4,971 | $4,656 |
| SG&A Expenses | $13,498 | $12,820 | $11,705 | $11,666 |
| Sales & Mktg Exp. | $6,839 | $7,163 | $6,734 | $7,010 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18,674 | $16,743 | $15,001 | $14,625 |
| Operating Income | -$9,014 | -$7,332 | -$7,329 | -$7,580 |
| % Margin | -77.9% | -65.4% | -79.9% | -91.8% |
| Other Income/Exp. Net | -$1,792 | -$959 | -$3,041 | -$2,529 |
| Pre-Tax Income | -$10,806 | -$8,291 | -$10,370 | -$10,109 |
| Tax Expense | $5 | -$3 | $5 | -$1 |
| Net Income | -$10,811 | -$8,288 | -$10,375 | -$10,108 |
| % Margin | -93.5% | -73.9% | -113.2% | -122.4% |
| EPS | -0.96 | -0.27 | -0.39 | -0.41 |
| % Growth | -255.6% | 30.8% | 4.9% | – |
| EPS Diluted | -0.96 | -0.27 | -0.39 | -0.41 |
| Weighted Avg Shares Out | 43,058 | 32,899 | 28,527 | 26,502 |
| Weighted Avg Shares Out Dil | 43,058 | 32,899 | 28,527 | 26,502 |
| Supplemental Information | – | – | – | – |
| Interest Income | $170 | $134 | $74 | $57 |
| Interest Expense | $1,460 | $1,423 | $1,209 | $1,068 |
| Depreciation & Amortization | $163 | $165 | $172 | $193 |
| EBITDA | -$9,183 | -$6,703 | -$8,989 | -$8,848 |
| % Margin | -79.4% | -59.8% | -98.1% | -107.1% |